A study published recently in the Journal of the American Medical Association has found that administering zoledronic acid every 12 weeks instead of the current standard of every four weeks over two years, does not increase the risk of skeletal-related events (SREs) in patients with bone complications due to breast cancer, prostate cancer or myeloma.…
These guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Berenson A et al. Ann Hematol. 2016 Dec 8. [Epub ahead of print]. Practical Considerations in Managing Relapsed Multiple Myeloma. Agarwal A et al. Clin Lymphoma Myeloma Leuk. 2016 Nov 23. pii: S2152-2650(16)30873-4. doi: 10.1016/j.clml.2016.11.010. [Epub ahead of print]. Effects of Stress Appraisal on the Quality of Life of Adult Patients with Multiple Myeloma and Their Primary Family…
Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study. Hansen PB et al. Support Care Cancer. 2016 Dec 13. [Epub ahead of print]. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Di Nisio M et al. Cochrane Database Syst Rev. 2016 Dec…
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Jones JR et al. Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114. Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. Hinduja A et al. PLoS One. 2016 Nov 30;11(11):e0166627. doi: 10.1371/journal.pone.0166627. eCollection 2016. Bullous skin lesions in a patient…
Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Skerget M et al. Radiol Oncol. 2016 May 12;50(4):402-408. eCollection 2016. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma – a phase II…
Results from the national Myeloma XI trial have shown a higher incidence of second primary malignancies (SPM) in patients receiving Revlimid (lenalidomide) maintenance treatment compared to those who did not, in line with other previous reported trials. Published in the Blood Cancer Journal analysis of the data showed that, although the overall incidence of SPM was…
Celgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences (UAMS) have announced that they have partnered to create the Myeloma Genome Project to compile high quality genetic and clinical data to improve diagnosis, prognosis and treatment for myeloma patients. The aim is to develop a strategy for classifying myeloma into subgroups…
Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. Malard F et al. Cancer Treat Rev. 2016 Nov 15;52:41-47. doi: 10.1016/j.ctrv.2016.11.005. [Epub ahead of print]. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Musto P et al. Ann Oncol. 2016 Nov 17. pii: mdw606. [Epub ahead of print]. Aging, ‘Treating the Older Patient’. Rosko A et al. Biol…
